Skip to main content
Elsevier
View Cart

Rapid Acting Antidepressants

  • 1st Edition, Volume 89 - June 26, 2020
  • Latest edition
  • Editors: Ronald S. Duman, John H. Krystal
  • Language: English

The Advances in Pharmacology series presents a variety of chapters from the best authors in the field.… Read more

World Book Day celebration

Where learning shapes lives

Up to 25% off trusted resources that support research, study, and discovery.

Explore resources

Description

The Advances in Pharmacology series presents a variety of chapters from the best authors in the field.

Key features

  • Includes the authority and expertise of leading contributors in pharmacology
  • Presents the latest release in the Advances in Pharmacology series

Readership

Investigators in neuroscience, pharmacology, neurology, psychiatry, medicine

Table of contents

Part I – Neurobiology of ketamine effects

    1. Effects of ketamine and other rapidly acting antidepressants on hippocampal excitatory and inhibitory transmission

Allie J. Widman and Lori L. McMahon

  • Antidepressant mechanisms of ketamine: Focus on GABAergic inhibition

    •

    Bernhard Luscher, Mengyang Feng and Sarah J. Jefferson

  • The role of eEF2 kinase in the rapid antidepressant actions of ketamine

    •

    Kanzo Suzuki and Lisa M. Monteggia

    Part II – The rapid therapeutic effects of ketamine

  • Clinical overview of NMDA-R antagonists and clinical practice

    •

    Pasha A. Davoudian and Samuel T. Wilkinson

  • Ketamine for depression clinical issues

    •

    Syed Z. Iqbal and Sanjay J. Mathew

  • Chronic stress pathology and ketamine-induced alterations in functional connectivity in major depressive disorder: An abridged review of the clinical evidence

    • Lynnette A. Averill, Samar Fouda, James W. Murrough and Chadi G. Abdallah

  • Neurobiological biomarkers of response to ketamine

    •

    Bashkim Kadriu, Elizabeth D. Ballard, Ioline D. Henter, Stephen Murata, Nimesha Gerlus and Carlos A. Zarate Jr

  • Relapse prevention in treatment resistant major depressive disorder with rapid-acting antidepressants

    •

    Jaskaran B. Singh, Maggie Fedgchin, Ella J. Daly and Wayne C. Drevets

  • The emergence of ketamine as a novel treatment for posttraumatic stress disorder

    •

    Adriana Feder, Sarah B. Rutter, Daniela Schille and Dennis S. Charney

    Part III – Novel rapid-acting antidepressant mechanisms related to ketamine

  • mGlu2/3 receptor as a novel target for rapid acting antidepressants

    •

    Shigeyuki Chaki

  • Involvement of muscarinic receptor mechanisms in antidepressant drug action

    •

    Jeffrey M. Witkin, Jodi L. Smith, Lalit K. Golani, Emily A. Brooks and Anna E. Martin

  • The antidepressant efficacy of the muscarinic antagonist scopolamine: Past findings and future directions

    •

    Wayne C. Drevets, Anindya Bhattacharya and Maura L. Furey

    Product details

    • Edition: 1
    • Latest edition
    • Volume: 89
    • Published: June 29, 2020
    • Language: English

    About the editors

    RD

    Ronald S. Duman

    Ronald Duman is at Yale University School of Medicine, CT, USA
    Affiliations and expertise
    Yale University School of Medicine, CT, USA

    JK

    John H. Krystal

    John Krystal is at Yale University, CT, USA
    Affiliations and expertise
    Yale University, CT, USA

    View book on ScienceDirect

    Read Rapid Acting Antidepressants on ScienceDirect